Skip to Content
Merck

Key Documents

View All Documentation

EHU096191

MISSION® esiRNA

targeting human STARD13 (1)

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

TGAGGCAAAAGAAGCATGTGACTGGCTCCGTGCTGCCGGGTTCCCGCAATACGCTCAGTTATATGAGGATTCACAATTTCCCATCAACATTGTGGCTGTCAAGAATGATCATGATTTTCTTGAAAAGGACCTTGTAGAACCTCTTTGCAGACGACTAAATACGTTGAACAAGTGTGCCTCAATGAAACTTGATGTGAACTTCCAAAGGAAAAAGAAGAGAAAAGGGACCCTTTAAGGATTCGAGATGACCTTCCCTGCCTCTGTAAGAGTCAGGTGGAGGAGTATTCTCGAGCTTAGCTGCACGCCTCACTGGAAGACTAACAACCCAGCCAAGAGC

Ensembl | human accession no.

ENSG00000133121

NCBI accession no.

NM_178006

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... STARD13(90627)

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chao Cheng et al.
American journal of cancer research, 8(7), 1200-1213 (2018-08-11)
To date, the anti-tumor mechanism of the deleted in liver cancer 2 (DLC2) in gliomas is still unclear. The study shows that TAp73α expression and TAp73α/TAp73β ratio are frequently high in gliomas and that TAp73α and TAp73β have opposite roles